Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

Roche’s mAb depletes regulatory T cells
Roche (SIX:ROG; OTCQX:RHHBY) and University College London scientists reported in Nature Cancer that the anti-CD25 mAb RG6292, which is in a Phase I trial in advanced solid tumor patients, depleted intratumoral regulatory T cells without blocking IL-2 signaling on bystander effector T cells in human tumor samples. RG6292 also depleted Tregs and activated tumor-infiltrating CD8⁺ T cells in humanized tumor-bearing mouse models and nonhuman primates with no sign of toxicity.

Immune-Onc’s mAb reprograms immune cells
Immune-Onc Therapeutics Inc. presented a poster this week at The Society for Immunotherapy of Cancer (SITC) meeting showing its LILRB2 antagonist IO-108 reprograms immune suppressive myeloid cells to a pro-inflammatory state which enhances T cell activation in patient-derived solid tumor samples. The company plans to submit an IND for IO-108 in 1H21...